Publications — Radcliffe Department of Medicine

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma.

Kurata K. et al, (2023), Blood Cancer J, 13

Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma.

Kurata K. et al, (2023), Blood Cancer J, 13

Prospective Assessment of Tumour Burden and Bone Disease in Plasma Cell Dyscrasias Using DW-MRI and Exploratory Bone Biomarkers.

Agarwal G. et al, (2022), Cancers (Basel), 15

Human bone marrow organoids for disease modelling, discovery and validation of therapeutic targets in hematological malignancies.

Khan AO. et al, (2022), Cancer Discov

Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma.

Gooding S. et al, (2022), Blood, 140, 1816 - 1821

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma.

Ansari-Pour N. et al, (2022), Blood

Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma.

Sudha P. et al, (2022), Clin Cancer Res, 28, 2854 - 2864

Proceedings from the BMT CTN Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma.

Holstein SA. et al, (2022), Transplant Cell Ther

Precision medicine for liver tumours with quantitative MRI and whole genome sequencing (Precision1 trial): study protocol for observational cohort study.

Welsh FK. et al, (2022), BMJ open, 12

Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T cell response.

Ramasamy K. et al, (2022), Br J Haematol

Multiple Myeloma Patient Tumors With High Levels of Cereblon Exon-10 Deletion Splice Variant Upregulate Clinically Targetable Pro-Inflammatory Cytokine Pathways.

Karagoz K. et al, (2022), Frontiers in genetics, 13

Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myeloma.

Chen LY. and Gooding S., (2022), Front Oncol, 12

COVID symptoms, testing, shielding impact on patient-reported outcomes and early vaccine responses in individuals with multiple myeloma.

Ramasamy K. et al, (2021), Br J Haematol

Myeloma clinical outcomes following the first wave of COVID-19: results from the Thames Valley Cancer Alliance (UK).

Sharpley FA. et al, (2021), Br J Haematol, 192, e136 - e139

Myeloma care adaptations in the UK during SARS-CoV-2 pandemic: Challenges and measurable outcomes.

Djebbari F. et al, (2020), Eur J Haematol, 105, 662 - 666

Multiple Cereblon genetic changes associate with acquired resistance to Lenalidomide or Pomalidomide in Multiple Myeloma.

Gooding S. et al, (2020), Blood

Gremlin 1 - small protein, big impact: the multiorgan consequences of disrupted BMP antagonism†.

Gooding S. and Leedham SJ., (2020), J Pathol

Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease.

Gooding S. et al, (2019), Nat Commun, 10

Multiple myeloma increases nerve growth factor and other pain-related markers through interactions with the bone microenvironment.

Olechnowicz SWZ. et al, (2019), Sci Rep, 9

Hepcidin is regulated by promoter-associated histone acetylation and HDAC3.

Pasricha S-R. et al, (2017), Nat Commun, 8

Load More

Include forthcoming?